$28.81
1.37% today
Nasdaq, Feb 28, 05:15 pm CET
ISIN
US8292141053
Symbol
SLP

Simulations Plus, Inc. Stock price

$29.21
-4.80 14.11% 1M
-7.40 20.21% 6M
+1.32 4.73% YTD
-12.84 30.54% 1Y
-10.18 25.84% 3Y
-6.39 17.95% 5Y
+22.85 359.28% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.17 3.85%
ISIN
US8292141053
Symbol
SLP

Key metrics

Market capitalization $586.90m
Enterprise Value $570.05m
P/E (TTM) P/E ratio 72.28
EV/FCF (TTM) EV/FCF 50.76
EV/Sales (TTM) EV/Sales 7.66
P/S ratio (TTM) P/S ratio 7.88
P/B ratio (TTM) P/B ratio 3.18
Dividend yield 0.82%
Last dividend (FY24) $0.24
Revenue growth (TTM) Revenue growth 19.84%
Revenue (TTM) Revenue $74.44m
EBIT (operating result TTM) EBIT $5.60m
Free Cash Flow (TTM) Free Cash Flow $11.23m
Cash position $18.17m
EPS (TTM) EPS $0.40
P/E forward 61.49
P/S forward 6.49
EV/Sales forward 6.31
Short interest 13.98%
Show more

Is Simulations Plus, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Simulations Plus, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Simulations Plus, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Simulations Plus, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Simulations Plus, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
74 74
20% 20%
100%
- Direct Costs 31 31
127% 127%
42%
44 44
10% 10%
58%
- Selling and Administrative Expenses 25 25
20% 20%
33%
- Research and Development Expense 6.39 6.39
40% 40%
9%
12 12
6% 6%
17%
- Depreciation and Amortization 6.84 6.84
71% 71%
9%
EBIT (Operating Income) EBIT 5.60 5.60
39% 39%
8%
Net Profit 8.22 8.22
23% 23%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Simulations Plus, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Simulations Plus, Inc. Stock News

Neutral
Business Wire
24 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending...
Neutral
Business Wire
about one month ago
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advan...
Neutral
Business Wire
about 2 months ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
More Simulations Plus, Inc. News

Company Profile

Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.

Head office United States
CEO Shawn O'Connor
Employees 247
Founded 1996
Website www.simulations-plus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today